Amylin Pharmaceuticals, Inc.

Astrazeneca Pharmaceuticals LP

Mitokor, Inc.

Migenix, Inc.

Siska Diagnostics, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Novo Nordisk A/s

Other

University of California

Pfizer Corporation

Smithkline Beecham Corporation

Vanderbilt University

Aegerion Pharmaceuticals, Inc.

Amryt Pharmaceuticals Inc.

Soumitra S Ghosh

Odile Esther Levy

Robert E Davis

Christopher Joseph Soares

David Geoffrey Parkes

Carolyn M Jodka

Lawrence J D'Souza

Michael R Hanley

Mary Erickson

Christine Marie Mack

Richard A Pittner

Diana Y Lewis

Tomas R Szabo

Walter H Moos

Yazhong Pei

Eoin D Fahy

Andrew A Young

Kathryn Susan Prickett

Ved Srivastava

Alain D Baron

Corinna Herrnstadt

William Christensen Clevenger

Jonathan David Roth

Scott W Miller

Samuel Janssen

Emil T Kaiser

David C Litzinger

Christen M Anderson

Qing Lin

Gary F Musso

Zijian Guo

Josue Alfaro-Lopez

John S Ahn

Abhinandini Sharma

Geoffrey M Wahl

Leslie E Orgel

Sandra Eileen Wiley

Sean H Adams

Thao Le

James A Dykens

Lawrence J D'souza

Alan Thomas Remaley

Madhav N Devalaraja

Chih-Hung Lo

Chengzao Sun

G&ouml;n&uuml;l Veli&ccedil;elebi

Caroline Ekblad

Denis O Sviridov

Anna Wolska

Manoj P Samant

Lala Mamedova

John S Kiely

Xiao-Qing Tang

Spiros Liras

Anne N Murphy

Michael K Ahlijanian

Christopher A Rhodes

Alan Cherrington

Behrouz Bruce Forood

William Davis Parker

Robert Terkeltaub

Gary Luo

Eugene Coats

Jennifer K Ishii

David Maggs

Swetha Neravetla

Sarah McQuaid

Andrew E Granston, Jr

Jui-Chen Lin

Ian William James

Esther Odile Levy

Lawrence D'SOUZA

Diana Yvonne Lewis

Carolyn Marie Jodka

The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

ApoC-II mimetic peptides

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including once weekly administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including lipodystrophy, dyslipidemia, hyperlipidemia, overweight, obesity, hypothalamic amenorrhea, Alzheimer's disease, leptin deficiency, fatty liver disease or diabetes (including type I and type II). Additional diseases and disorders which can be treated by the compounds and methods described herein include nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD), metabolic syndrome X and Huntington's Disease.

Engineered polypeptides having enhanced duration of action

This disclosure provides methods for treatment comprising co-administering insulin and glucagon to a subject, and co-formulations comprising insulin and glucagon.

Systems, compositions and methods for treating diabetes

Engineered polypeptides having enhanced duration of action and reduced immunogenicity

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, short bowel syndrome, Parkinson's disease, cardiovascular disease, and other and disorders of the central nervous system.

The present invention relates generally to novel, selectable hybrid polypeptides useful as agents for the treatment and prevention of metabolic diseases and disorders which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, such as diabetes and diabetes-related conditions. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

Hybrid polypeptides with selectable properties

Compounds are provided having inter alia good duration of action, high potency and/or convenient dosing regimens including oral administration, and reduced immunogenicity. The compounds are engineered polypeptides which incorporate an albumin binding domain in combination with one or more biologically active polypeptides. Also provided are pharmaceutical compositions and methods of treatment for diseases and disorders including obesity and overweight, diabetes, dyslipidemia, hyperlipidemia, Alzheimer's disease, fatty liver disease, Short Bowel Syndrome, Parkinson's disease, and cardiovascular disease.

Engineered polypeptides having enhanced duration of action with reduced immunogenicity

There are provided compounds and methods for amidating the C-terminus of a polypeptide. The methods include reacting a polypeptide which includes a C-terminal thioester or C-terminal selenoester with any one of a defined set of auxiliary molecules under conditions suitable to produce a polypeptide adduct which includes the auxiliary molecule chemically bound at the C-terminal of the polypeptide. The auxiliary molecule can be a substituted or unsubstituted 2-phenyl-2-amino ethanethiol, a substituted or unsubstituted 2-phenyl-2-amino ethaneselenol, or a substituted xanthene. In the subsequent step, a portion of the auxiliary molecule is removed from the C-terminal of the polypeptide adduct and leaving the amide nitrogen under conditions suitable to form a C-terminal free amide polypeptide.

C-terminal amidation of polypeptides

The disclosure provides GLP-1 receptor agonist compounds having stabilized regions corresponding to alpha-helical regions of the natural peptide compounds. The disclosure also provides benzamide-containing exendin-4 analogs and alkene-constrained exendin-4 analogs, both of which have stabilized regions corresponding to alpha-helical regions of exendin-4.

GLP-1 receptor agonist compounds having stabilized regions

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.

GIP analog and hybrid polypeptides with selectable properties

The present invention provides novel Pancreatic Polypeptide Family ('PPF') polypeptides and methods for their use.

Pancreatic polypeptide family motifs, polypeptides and methods comprising the same

GIP and exendin hybrid polypeptides

Peptide-peptidase inhibitor conjugate molecules are disclosed. These conjugate molecules are useful as agents for the treatment and prevention of metabolic and cardiovascular diseases, disorders, and conditions. Such diseases, conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, insulin-resistance, obesity, and diabetes mellitus of any kind, and other diabetes-related disorders.

Peptide-peptidase inhibitor conjugates and methods of using same

Growing community of inventors

San Diego, CA, United States of America

Soumitra S Ghosh